Cisplatin nephrotoxicity affects magnesium and calcium metabolism.
Cisplatin is not directly toxic to bone, but cisplatin nephrotoxicity leading to magnesium wasting may affect magnesium and calcium metabolism, both of which contribute to bone integrity. The specificity of the magnesium lesion suggests that cisplatin may have an affinity for proteins that regulate magnesium absorption. Sulfhydryls such as amifostine can reduce the toxicity of cisplatin in adults, but current pediatric data do not indicate a role for sulfhydryl therapy to reduce cisplatin toxicity in children.
Goren
Marshall P
MP
Department of Urology, The University of Tennessee, Memphis, Tennessee, USA. mgoren@utmem.edu
D000328:Adult; D004999:Amifostine / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002118:Calcium / Q000378:metabolism*; D002648:Child; D002945:Cisplatin / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D006801:Humans; D007668:Kidney / Q000187:drug effects* / Q000378:metabolism; D007674:Kidney Diseases / Q000139:chemically induced* / Q000378:metabolism; D008274:Magnesium / Q000378:metabolism*; D008275:Magnesium Deficiency; D018384:Oxidative Stress; D011837:Radiation-Protective Agents / Q000627:therapeutic use; D014883:Water-Electrolyte Imbalance
D000970:Antineoplastic Agents; D011837:Radiation-Protective Agents; D008274:Magnesium; D004999:Amifostine; D002945:Cisplatin; D002118:Calcium